Skip to content

Pemvidutide

Also called ALT-801

GLP-1/glucagon dual agonist.

  • TypePeptide
  • FormInjectable
  • Researched forMetabolic & Fat Loss
Join Skool for the protocol

No partner carries Pemvidutide yet.

The short version

  • Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
  • What the evidence isIn phase 2.
  • What to watchSevere belly pain that spreads to the back while using Pemvidutide.

How Pemvidutide works

GLP-1/glucagon dual agonist — glucagon arm drives energy expenditure and hepatic fat loss on top of GLP-1 appetite control.

The first thing to fix is which drug this is. Pemvidutide is sold on this site as a weight-loss compound, and the entire peer-reviewed record for it is liver: three randomized trials, all in fatty liver disease, two of them with a biopsy or an MRI endpoint Harrison 2024 Browne 2025 Noureddin 2025.

The mechanism: GLP-1 plus glucagon, and the glucagon arm is the whole point. A GLP-1 receptor agonist reduces intake. A glucagon receptor agonist increases expenditure and, specifically, drives hepatic fat oxidation — the liver burns its own stored triglyceride.

  • Injectable

On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)

Where to get Pemvidutide

No partner carries it yet.

When a vetted partner does, the link and code go here.

Research on Pemvidutide5 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Human clinical evidence

  • In phase 2. Altimmune's GLP-1/glucagon dual agonist. The MOMENTUM obesity trial reported around 15.6% weight loss at 48 weeks, with the company highlighting that roughly 75% of the loss was fat mass rather than lean — unusually high preservation for this class.

  • Phase 2 in MASH reported significant liver fat reduction. Lean-mass preservation is a claim to watch rather than accept — body-composition sub-studies are small and methodologically variable.

Correlative data

  • No marketed use. Trial tolerability is class-typical, with the glucagon-driven heart rate increase noted as with the other duals.

How the mechanism reads

  • A GLP-1/glucagon dual agonist engineered with a 1:1 receptor ratio — a deliberately higher glucagon weighting than most competitors, using a lipid modification for duration.

    Mechanistic
  • The ratio is the whole design thesis. More glucagon means more energy expenditure and more hepatic fat oxidation, which is the mechanistic case for both the lean-mass and liver findings. It also means more of glucagon's downsides, and where the optimal ratio sits is genuinely unsettled.

    Mechanistic

Sources

  • Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. Journal of Hepatology 2024 · PMID 39002641
  • Browne SK, et al. Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. JHEP Reports 2025 · PMID 41113119
  • Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet 2025 · PMID 41237796
  • Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine 2024 · PMID 38858523
  • Guo W, et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Molecular Metabolism 2023 · PMID 37364710
  • Li F, et al. Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Diabetes, Obesity and Metabolism 2026 · PMID 42310888
  • Yang Y, et al. Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis. Diabetes, Obesity and Metabolism 2023 · PMID 37860884
  • He L, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine 2022 · PMID 35344001
  • Stefanakis K, et al. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism 2024 · PMID 39481534
  • Muller TD, et al. Anti-obesity drug discovery: advances and challenges. Nature Reviews Drug Discovery 2022 · PMID 34815532

Pemvidutide safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Medullary thyroid cancer or MEN2 in the family: the GLP-1 arm of pemvidutide shares the rodent C-cell signal.
  • Decompensated cirrhosis: the glucagon arm acts on the liver, and a failing liver is untested.
  • Pancreatitis history, or type 1 diabetes and insulin use.
  • Pregnancy or conception plans: glucagon-receptor activity in a fetal liver has no human data.

What’s expected

  • Falling appetite and weight from the GLP-1 arm.
  • Marked drop in liver fat and liver enzymes, from balanced glucagon receptor activity.
  • Nausea and loose stools early.
  • A small rise in resting pulse.

Watch for

  • Severe belly pain that spreads to the back while using Pemvidutide.
  • Yellow eyes, dark urine or pale stools.
  • Heart pounding at rest while using Pemvidutide.
  • Vomiting that will not settle.

Labs that tell you it’s working

  • Comprehensive Metabolic Panel (CMP)
  • Lipase
  • Lipid Panel
  • Enhanced Liver Fibrosis (ELF) Test

Balanced GLP-1 and glucagon agonist built for fatty liver; liver enzymes show it working, lipase shows pancreas stress. PMID 39002641 PMID 41237796

Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON

A panel picked from how it works and what it can move: the tests, and why each is on it.

9 tests in one order
Marek Diagnostics · no doctor’s visit
Code CAMERON
Order this panel

Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.

The Metabolic Health & Prediabetes panel, explained

Pemvidutide FAQ4 common questions

Is Pemvidutide approved for human use?
No. Pemvidutide is a research compound.
What is Pemvidutide researched for?
Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Which labs show whether it's doing anything?
Comprehensive Metabolic Panel; Lipase; Lipid Panel; Enhanced Liver Fibrosis: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Pemvidutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Pemvidutide is. Skool covers how it is run.

Free on this page

What Pemvidutide is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Pemvidutide is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Join Skool for the protocol